 BURLINGAME, Calif.--BUSINESS WIRE--- HGEN--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that Cameron Durrant, chairman and chief executive officer of Humanigen, will present at two healthcare conferences in January 2022. The company and its management are also expected to meet with investors, analysts, bankers and potential partners during the conferences next wee 